| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Oncology |
| Manuscript Type |
Prospective Study |
| Article Title |
Weekly docetaxel and gemcitabine in previously treated metastatic esophageal squamous cell carcinoma
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Min-Young Lee, Ki Sun Jung, Hae Su Kim, Ji Yun Lee, Sung Hee Lim, Moonjin Kim, Hyun Ae Jung, Sung Min Kim, Jong Mu Sun, Myung-Ju Ahn, Jeeyun Lee, Se Hoon Park, Seong Yoon Yi, In Gyu Hwang, Sang-Cheol Lee, Hee Kyung Ahn, Do Hyoung Lim, Soon Il Lee and Keon Woo Park |
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| Dong-A ST (Seoul, Korea) for kindly provided the study drug (gemcitabine) |
|
|
| Corresponding Author |
Keon Woo Park, MD, Division of Hematology-Oncology, Department of Internal Medicine, Dankook University College of Medicine, 16-5 Anseo-Dong, Dongnam-Gu, Cheonan 330-715, South Korea. pkw800041@naver.com |
| Key Words |
Clinical trial; Phase Ⅱ; Chemotherapy; Carcinoma; Esophageal neoplasm; Squamous cell; Docetaxel; Gemcitabine |
| Core Tip |
Esophageal squamous cell carcinoma (SCC) is a lethal disease with a poor prognosis. Currently, there is no standard chemotherapy regimen for metastatic esophageal SCC patients who have failed platinum and fluoropyrimidine combination chemotherapy. In this multi-center, prospective phase Ⅱ study, we demonstrated that the combination of weekly docetaxel and a fixed-dose rate of gemcitabine is active and well tolerated as a salvage chemotherapy in patients with previously treated metastatic esophageal SCC. |
| Publish Date |
2015-04-15 11:01 |
| Citation |
Lee MY, Jung KS, Kim HS, Lee JY, Lim SH, Kim M, Jung HA, Kim SM, Sun JM, Ahn MJ, Lee J, Park SH, Yi SY, Hwang IG, Lee SC, Ahn HK, Lim DH, Lee SI, Park KW. Weekly docetaxel and gemcitabine in previously treated metastatic esophageal squamous cell carcinoma. World J Gastroenterol 2015; 21(14): 4268-4274 |
| URL |
http://www.wjgnet.com/1007-9327/full/v21/i14/4268.htm |
| DOI |
http://dx.doi.org/10.3748/wjg.v21.i14.4268 |
